OBJECTIVE: To determine the therapeutic efficacy of adjuvant use of voriconazole, 1%, eyedrops in the treatment of refractory fungal keratitis. METHODS: A prospective open-label trial was conducted to determine voriconazole levels obtained in human aqueous humor after administration of a 1% solution, preserved with 0.01% benzalkonium chloride, every 6 hours for 3 days, or hourly for 4 doses. Ten participants were selected among patients scheduled to undergo elective anterior segment surgery, and samples were tested using validated high-performance liquid chromatography. RESULTS: The mean (SD) voriconazole concentrations after hourly dosing (n = 5) was 1.90 (1.12) microg/mL and after a single dosing every 6 hours (n = 5) was 0.94 (1.21) microg/mL, respectively. The mean (SD) sampling times after the last administration of eyedrops were 1.1 (0.5) hours after hourly dosing and 2.1 (0.6) hours after a single dosing every 6 hours. CONCLUSIONS: Voriconazole, 1%, eyedrops are well tolerated and penetrate into human aqueous humor when administered at hourly or 6-hourly intervals. They are effective in treating Candida and Aspergillus keratitis, are substantially more affordable than oral therapy, and have less potential to cause systemic adverse effects.
OBJECTIVE: To determine the therapeutic efficacy of adjuvant use of voriconazole, 1%, eyedrops in the treatment of refractory fungal keratitis. METHODS: A prospective open-label trial was conducted to determine voriconazole levels obtained in human aqueous humor after administration of a 1% solution, preserved with 0.01% benzalkonium chloride, every 6 hours for 3 days, or hourly for 4 doses. Ten participants were selected among patients scheduled to undergo elective anterior segment surgery, and samples were tested using validated high-performance liquid chromatography. RESULTS: The mean (SD) voriconazole concentrations after hourly dosing (n = 5) was 1.90 (1.12) microg/mL and after a single dosing every 6 hours (n = 5) was 0.94 (1.21) microg/mL, respectively. The mean (SD) sampling times after the last administration of eyedrops were 1.1 (0.5) hours after hourly dosing and 2.1 (0.6) hours after a single dosing every 6 hours. CONCLUSIONS:Voriconazole, 1%, eyedrops are well tolerated and penetrate into human aqueous humor when administered at hourly or 6-hourly intervals. They are effective in treating Candida and Aspergillus keratitis, are substantially more affordable than oral therapy, and have less potential to cause systemic adverse effects.
Authors: Daoud Al-Badriyeh; Lok Leung; Trent Roydhouse; Robert Fullinfaw; Mark Daniell; Geoffrey E Davies; Kay Stewart; David C M Kong Journal: Antimicrob Agents Chemother Date: 2009-05-11 Impact factor: 5.191
Authors: Namperumalsamy V Prajna; Jeena Mascarenhas; Tiruvengada Krishnan; P Ravindranath Reddy; Lalitha Prajna; Muthiah Srinivasan; C M Vaitilingam; Kevin C Hong; Salena M Lee; Stephen D McLeod; Michael E Zegans; Travis C Porco; Thomas M Lietman; Nisha R Acharya Journal: Arch Ophthalmol Date: 2010-06
Authors: Chin Fen Neoh; Lok Leung; Elsie Chan; Daoud Al-Badriyeh; Robert O Fullinfaw; Vishal Jhanji; Rasik B Vajpayee; Geoffrey E Davies; Kay Stewart; David C M Kong Journal: Antimicrob Agents Chemother Date: 2016-10-21 Impact factor: 5.191
Authors: P Troke; G Obenga; T Gaujoux; P Goldschmidt; A-L Bienvenu; M Cornet; F Grenouillet; D Pons; S Ranque; K Sitbon; C Chaumeil; V Borderie; O Lortholary Journal: Infection Date: 2012-06-21 Impact factor: 3.553
Authors: Prajna Lalitha; N Venkatesh Prajna; Catherine E Oldenburg; Muthiah Srinivasan; Tiruvengada Krishnan; Jeena Mascarenhas; C M Vaitilingam; Stephen D McLeod; Michael E Zegans; Travis C Porco; Nisha R Acharya; Thomas M Lietman Journal: Cornea Date: 2012-06 Impact factor: 2.651
Authors: Catherine Q Sun; N Venkatesh Prajna; Tiruvengada Krishnan; Jeena Mascarenhas; Revathi Rajaraman; Muthiah Srinivasan; Anita Raghavan; Kieran S O'Brien; Kathryn J Ray; Stephen D McLeod; Travis C Porco; Nisha R Acharya; Thomas M Lietman Journal: Invest Ophthalmol Vis Sci Date: 2013-06-14 Impact factor: 4.799
Authors: Catherine Q Sun; Prajna Lalitha; N Venkatesh Prajna; Rajarathinam Karpagam; Manoharan Geetha; Kieran S O'Brien; Catherine E Oldenburg; Kathryn J Ray; Stephen D McLeod; Nisha R Acharya; Thomas M Lietman Journal: Ophthalmology Date: 2014-04-16 Impact factor: 12.079